ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose escalation study of ASLAN001 given in combination with
CAPOX or mFolfox6, in patients with metastatic solid tumours, whom are suitable to receive
CAPOX or mFolfox6, or with tumours that have dysregulated EGFR or HER2 signaling.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborators:
Aslan Pharmaceuticals National Medical Research Council (NMRC), Singapore